When the “second wave” of Covid-19 hit the world, there was only one hope – and it lay with countries which have begun vaccination programs.
Undoubtedly the discovery of the Covid-19 vaccine is a major achievement. But the global debate over the vaccine is that it is creating a new inequality between rich and poor countries. Rich countries have already bought a large stock of vaccines due to their financial capacity.
Now people from rich countries are getting vaccinated. However, if the poorer countries do not get the shot, most people in the world will remain unprotected. It is suspected that the pandemic will be prolonged. In the meantime, new variants of the virus have been emerging with rapidity.
As a result, though much progress has been made in vaccination, the measures may be threatened again.
Mariana Mazzucato, Jayati Ghosh and Els Torreele have written an article on such inequality and intellectual property issues in The Economist.
Mazzucato is an economics professor at University College London. Jayati is also a professor of economics at the University of Massachusetts at Amherst. And Torreele is a visiting fellow at the Institute for Innovation and Public Purpose.
They all are part of the People’s Vaccine Alliance, an initiative to rapidly develop a free Covid vaccine for all people by suspending intellectual-property rights on the technology.
According to them, the solution to the current situation is to vaccinate people — everyone will get it and everyone will have access to it. Vaccination of these people can pave the way for the removal of the discrimination that is being noticed at present.
The authors believe that the shortage of vaccines has been artificially created and that this situation can be avoided. The whole world could have produced this vaccine together if there were no intellectual property issues.
It was possible to give this vaccine to 60% of the world's people this year and to all those who want it by 2022. But this scarcity has been created as rich countries stockpile vaccines and pharmaceutical companies stockpile technology.
Starting from Bangladesh, many companies from countries like Canada are ready to make this vaccine, but the wait is for just a formula.
Despite their capabilities, they are unable to produce vaccines. If they could produce them, many more people would be vaccinated and the poor would be less dependent on rich countries.
Pharmaceutical companies, however, say they can increase production on their own. But their words have turned into lanterns. In rich countries, they are not able to supply as promised. AstraZeneca and Johnson & Johnson are facing production challenges and are unable to supply Europe and North America. Pfizer and Moderna are mainly supplying in the US market, while others are getting very little.
This is where the intellectual property debate comes into play.
The production of vaccines is not increasing due to patents, as pharmaceutical companies have bought vaccine formulas - their exclusive right over production. Those who have bought licenses from them again will be able to produce, not others. As a result, the production and distribution of vaccines is limited to them.
This intellectual property is managed in the light of the Trade Related Aspects of Intellectual Property Rights (TRIPS) Agreement, originally signed under the auspices of the World Trade Organization (WTO).
Developing countries now demand that the terms of the agreement be relaxed in special circumstances. Many argue that TRIPS has this condition that those who have the capacity to produce are compulsorily licensed.
As a result, pharmaceutical companies in developing countries will be able to produce and distribute vaccines at much lower cost. Allegedly, the companies in developed countries are demanding more money in these difficult times.
The reality is that countries like Bangladesh, Uganda and South Africa are buying AstraZeneca vaccines at a higher price than the European Union.
Other companies are charging more. Pfizer said vaccine prices would rise if the situation improved. As can be seen then, Moderna and Johnson & Johnson have also started walking the same path.
The same applies to vaccines as well as medical supplies - the conditions related to intellectual property rights should be relaxed. The same applies to masks, PPEs, gloves — everything.
The point is that though the governments of different countries invested huge dollops of money in creating this knowledge, it has remained in the hands of the private sector. There is a whiff of immorality about it. This money came from people's taxes. As a result, people should naturally have control over this knowledge.



